What Makes a Good Medical Device Adverse Event Report?

Slides:



Advertisements
Similar presentations
Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance.
Advertisements

Challenges in Using a Formal Decision Analysis Approach to Medical Device Approval Larry Kessler, Sc.D. Director, Office of Science and Engineering Laboratories.
1 Danica Marinac – Dabic, M.D., Ph.D. Chief, Epidemiology Branch Office of Surveillance and Biometrics Center for Devices and Radiological Health Postmarket.
Overview of Device Regulations David Arvelo Small Business Representative.
Humanitarian Device Exemptions (HDE) 101 Elizabeth Hillebrenner, MSE Biomedical Engineer IDE and HDE Program Staff Center for Devices and Radiological.
Electronic Fetal Monitors Case Study Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices.
Agenda The role of MHRA, Hospitals and the Manufacturer
Introduction to Regulation
Pharmacovigilance and Risk Management Chapter 17.
Medical Devices Approval Process
MONDAY, 5:00 – 5:30PM Innovative Opportunities for Patient Safety Using Electronic Health Record (EHR) Data: Perspectives from the FDA FDA to CONNECT Mitra.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
CE marking Catriona Blake Team Manager, Imaging, acute and community care.
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
William B Munier, MD, MBA, Director Center for Quality Improvement and Patient Safety Agency for Healthcare Research and Quality AHRQ Annual Conference.
Center for Devices and Radiological Health U. S. Department of Health and Human Services Al Taylor Acting Chief, Medical Electronics Branch Office of Science.
Weaving regulations into sound value analysis processes Barbara Strain, MA, SM(ASCP) Director Value Management University of Virginia Health System.
Unique Device Identification and Global Medical Device Nomenclature Jay Crowley Senior Advisor for Patient Safety Food and Drug Administration
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’
Adverse Event Reports on Automatic External Defibrillators from Oscar H Tovar MD and Beverly Gallauresi RN, MPH Food and Drug Administration.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.
Safety & Efficacy Update on Approved TNF-Blocking Agents Jeffrey N. Siegel, M.D. OTRR, CBER / FDA Arthritis Advisory Committee March 4, 2003 Jeffrey N.
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
The Food and Drug Administration Amendments Act of 2007: Implications of the Drug Safety Provisions Carolyn D. Jones, J.D., MPh Director, Regulatory Policy.
NORTH AMERICAN SAFETY CHECKLIST – SB 158. Rhonda Anderson, RHIA President Anderson Health Information Systems, Inc. Presented By:
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
1 OPHS FOUNDATIONAL STANDARD BOH Section Meeting February 11, 2011.
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
MassMEDIC Risk Management: Legal and Liability Issues with Home Healthcare Products Raymond C. Zemlin Goodwin Procter LLP (March 9, 2006) ©2006. Goodwin.
Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,
Incident Reports and field Safety Corrective Action ( FSCA) Eng. Essam M. Al-Mohandis Executive Director of Surveillance and Biometrics.
1 Medical Device Safety Susan Gardner, Ph.D. Director, Office of Surveillance and Biometrics Center for Devices and Radiological Health.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.
FDA Focus On Consumer Protection
M-CERSI Workshop – Envisioning the Future of Mobile Informatics Division of Postmarket Surveillance 1 Overview I.What DPS does… II.The Brick Model… III.Where.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
Bibliography Amoore, J., Ingram, P. (2002, August). Quality improvement report: Learning from adverse incidents involving medical devices. British Medical.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
CDRH INITIATIVES FOR AGING IN PLACE NIH Aging in Place Workshop September 10-11, 2014 Presented by Mary Brady, MSN, RN Senior Policy Advisor Center for.
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
1 CDRH: Minimizing Risk of TSE Agents in Medical Devices CDR Martha O’Lone, RN, BSN CDRH TSE Working Group Chair Infection Control Devices Branch DAGID.
Rules for Supporting Part 803 and Part 806 Decision Making Page 1 Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
1 Serious Adverse Events Following Falsely Elevated Glucose Measurements Resulting from Administration of an IGIV Product Containing Maltose BPAC Meeting,
Utah Life Science Summit Nov Phil Triolo, PhD RAC President, Phil Triolo and Associates LC.
Center for Devices and Radiological Health U. S. Department of Health and Human Services Al Taylor Acting Chief, Medical Electronics Branch Office of Science.
Drug & Poison Control center
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
1 Risk Management Considerations for Romiplostim Suzanne Berkman, PharmD Senior Risk Management Analyst Division of Risk Management Office of Surveillance.
DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® Septal Occlusion System with Qwik Load NMT Medical P
1 Disseminated Intravascular Coagulation Associated with Acute Hemoglobinemia and/or Hemoglobinuria following Rh o (D) Immune Globulin Intravenous Administration.
1 BETTER APPROACHES TO MONITORING MEDICAL PRODUCT SAFETY ARE NEEDED.
FDA Notifications and Medwatch Form Requirements Adverse Event Reporting for OTC Drugs and Dietary Supplements.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Medical Product Safety Network (MEDSUN) an Interactive Surveillance System: Eliminating Barriers to Reporting and Creating Two-Way Communication with FDA.
Clinical Review Process for New Drug Development and Application
HOSPITAL ACCREDITATION & RETAINING QUALITY
Understanding and learning from errors and managing clinical risks
Infusion Pump ROP Compliance
FDA Guidance for Industry and FDA Staff Summary of Public Notification of Emerging Postmarket Medical Device Signals (“Emerging Signals”) Effective: December.
FDA Sentinel Initiative
Tobey Clark, Director*, Burlington USA
Presentation transcript:

Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT

What Makes a Good Medical Device Adverse Event Report?

Complete Device Narrative Information Device Identifier data Device Type e.g. Infusion Pump Implantable insulin Patient controlled analgesia Brand Name e.g. Kleenex brand of tissues Model Number e.g. 123 or ABC defibrillator Manufacturer Name e.g. Check for name on device label

Complete Device Narrative Information User Demographics Who is using the device? healthcare professional patient Patient Diagnosis Any presenting or underlying condition that may have contributed to the reported adverse event Circumstances of Use Anything unusual or unexpected about the device use in the reported adverse event?

What Happens to Adverse Event Reports Submitted to the FDA?

Demographics 100,000 - 120,000 medical device adverse event reports per year 95% from manufacturers about half of these are summary reports 5% from health care practitioners, consumers, and user facilities

Reports are Evaluated The FDA’s CDRH relies on backgrounds in: Nursing Biology Radiology Dentistry Public health Chemistry Biomedical engineering

Adverse Event Evaluation High-Risk Reports receive priority review Pediatric deaths Multiple patient deaths or serious injuries Fire , explosion, electrocution Burn, anaphylaxis, exsanguination Manufacturer initiates remedial action Unusual events flagged by a reviewer

Adverse Event Evaluation High volume, well-known, events are reviewed in the aggregate through summary reporting Breast Implants Surgical Sutures Intravascular Catheters

Adverse Event Evaluation Reports are reviewed against other data FDA regulatory data such as pre-market submissions and product recalls Literature reviews Previously submitted adverse event trends similar problems with similar devices similar problems with other manufacturers similar patient or use scenarios

Adverse Event Evaluation Analysts may request additional information to assess the cause of a reported event by: telephone fax letter user facility visit manufacturer inspection consult with other FDA Centers

FDA Recommendations Public Health Notification Post-market Studies Regulatory Action Recalls, Standards Education and Outreach Peer-Reviewed Articles Websites Conferences, Partnerships with professional organizations

Unanswered Questions in the Post-market Period Long Term Medical Device Safety Data Condition of approval studies Post-market studies Device Performance in the Larger Post-market Patient Population Epidemiological Studies Registries Use Error Related to New and Complex Technology Changing User Demographics, i.e. professionals and lay consumers Variety of Use Locations, i.e. hospital and home Evolution of Multiple Function-Multiple Indication Devices, i.e. blood pressure monitors, fluid delivery systems

Medical Product Surveillance Network (MedSun) Data from a sample of medical facilities is anticipated to: Provide information on emerging medical device problems Provide information on changes in device use Promote communication between FDA and the clinical community Lead to improved safety and efficacy of medical device use